Biological treatment in severe psoriasis: Influence on peripheral blood dendritic cells

Scand J Immunol. 2023 Dec;98(6):e13321. doi: 10.1111/sji.13321. Epub 2023 Aug 13.

Abstract

In-depth immunophenotyping by flow cytometry of peripheral blood dendritic cell (DC) populations of psoriasis vulgaris without (PsO; N = 23) or with psoriatic arthritis (PsA; N = 15), before (T1) and after 12 months (T2) therapy with the anti-TNF drugs infliximab, etanercept, the anti-IL-17A secukinumab and the anti-IL12/IL-23 ustekinumab. Compared to healthy donors (N = 38), patients with PsA displayed lower frequencies of dendritic cell subsets pDC, cDC1 and cDC2, which were normalized following treatment except pDC. In contrast, patients with PsO only displayed lower frequencies of pDC which were normalized following treatment. Figure created with BioRender.com.

Publication types

  • Letter

MeSH terms

  • Arthritis, Psoriatic* / drug therapy
  • Blood Cells
  • Dendritic Cells
  • Humans
  • Psoriasis* / drug therapy
  • Tumor Necrosis Factor Inhibitors

Substances

  • Tumor Necrosis Factor Inhibitors